Next-Gen TIL Therapy With a Broader T-Cell Repertoire – The Key to Unlocking Less Immunogenic Solid Tumor Indications

Time: 2:30 pm
day: Day One


• Explore reinvigoration of exhausted TILs by ex vivo checkpoint blockade and stimulation generating a TIL product with a broader T-cell repertoire

• Investigate reduction in required starting material to a few milligrams of tumor allowing for minimally invasive TIL therapy to expand patient reach

• Examine T-cell repertoire breadth, depth and functionality – the way to boost clinical outcome of TIL therapy